Rise of the bio-pharmaceutical industry

Rise of the bio-pharmaceutical industry

What are bio-pharmaceuticals?

Bio-pharmaceuticals,informally known as, bio-pharma, are the point at which biotechnology and pharmaceutical manufacturing meet. It is the application of living organisms or extractions, by-products or components of living organisms, to prevent, relieve, or treat diseases.

Bio-pharma companies can make drugs from biological components of substances, including sugars, proteins, nucleic acids such as DNA and RNA, or complex combination of components. 

In simple terms, bio-pharmaceuticals are laboratory-created medicines that are structurally identical to compounds already found in nature.

When it all began.

Well, it certainly did not bolt from the blue, but began in the 19th century when scientists exploited the knowledge of using nature to cure diseases that they began to synthesize the active compound.

Bio-pharma today

Bio-pharmaceuticals are revolutionizing the world of medicine and saving the lives of thousands of people every day. Patients suffering from cancer, diabetes, cardiovascular disease, immune diseases, and other health problems already benefit from bio-pharmaceuticals, which provides targeted treatment and fewer side effects. Soon, billions of people around the world will benefit from this innovative approach to treating disease.

Bio-pharma is changing how doctors treat diabetes, cancer, and other diseases because it allows clinicians to tailor treatment to the specific medical problems experienced by each patient. Biotechnology allows researchers to use cell fusion, r-DNA technologies, and other technologies to modify treatments specifically for individual diseases.

Emerging bio-pharmaceutical technologies include the manufacture of monoclonal antibodies, which are identical immune cells that are clones of a unique parent cell, the design of chemically defined cells, and genome-based technologies that can improve the vaccine manufacturing process and create new cancer treatments.

The rise of bio-pharmaceuticals

Bio-pharmaceuticals are the world’s fastest-growing class of medicine.

https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/rapid-growth-in-biopharma

The global market for bio-pharmaceuticals is estimated at more than $200 billion, and the market is continuing to grow at around 8% annually. But there are also issues that the industry may have to face.

But the discussion to health care researchers about discovery, development and manufacturing of new drugs continues. Disciplines involving Drug Discovery, Pharmaceutical Manufacturing, Novel Drug Delivery Systems, Nanotechnology, Radio-pharmaceuticals, Clinical Trials, GMP, GCP & Regulatory Affairs, Packaging and Marketing are still in a developing stage. 7th European Biopharma Congress.

What's next for the bio-pharmaceutical?

The greatest potential for bio-pharma is in gene therapy. Conditions associated with rapidly dividing cells, such as cancer, develop as the result of defective or mutated genes. In gene therapy, scientists replace defective genes with healthy ones to treat existing disease or to prevent disease from developing later.

Bio-pharma will forever change how doctors treat diseases, and future patients will benefit from bio-pharmaceuticals in ways we can now only imagine. Bio-pharmaceuticals may one day eradicate many diseases that now plague humankind and shorten lives, such as diabetes, cancer, and heart disease.

Bio-phama started and continues its evolution in a booming industry. Only through a combination of strong science and deep operational excellence will the bio-pharma industry be able to fulfill its potential to transform the health expectations of millions of people across the globe, successfully navigating both the promising and challenging elements of the sector.
So do you think this rise in bio-pharma is beneficial for the pharmaceutical industry?